XML 18 R4.htm IDEA: XBRL DOCUMENT v3.26.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
OPERATING EXPENSES    
Research and development $ (9,737) $ (8,878)
General and administrative (10,503) (12,898)
Total operating expense (20,240) (21,776)
Loss from operations (20,240) (21,776)
OTHER INCOME (EXPENSES), NET    
Change in fair value of other liabilities and derivatives 1 285
Change in fair value of other liabilities and derivatives – related party 1 39
Grant income 50 181
Gain on sale of investment in Nova Cell 244
Other income, net 103 9
Total other income (expenses), net 192 (419)
LOSS BEFORE INCOME TAXES (20,048) (22,195)
Income tax provision (15) (14)
NET LOSS (20,063) (22,209)
Net loss attributable to noncontrolling interest (157) (66)
NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST (19,906) (22,143)
Deemed dividend on warrants (5,673) (1,671)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (25,579) $ (23,814)
Net loss per share, basic $ (5.95) $ (35.70)
Net loss per share, diluted $ (5.95) $ (35.70)
Weighted average common shares outstanding, basic 4,302 667
Weighted average common shares outstanding, diluted 4,302 667
Nonrelated Party [Member]    
OTHER INCOME (EXPENSES), NET    
Interest expense $ (131) $ (372)
Related Party [Member]    
OTHER INCOME (EXPENSES), NET    
Interest expense $ (76) $ (561)